FIXX · Homology Medicines, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $53.74M | $0 | $1.16M | $3.21M | $33.97M | $2.70M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $19.16M | $48.14M | $62.00M | $98.35M | $93.08M | $100.39M |
| SG&A | $17.68M | $17.96M | $31.26M | $38.14M | $36.84M | $32.57M |
| Total Operating Expenses | $36.84M | $66.10M | $102.58M | $136.49M | $129.92M | $132.97M |
| D&A | $391.0K | $487.0K | $578.0K | $1.29M | $8.35M | $7.96M |
| Operating Income | $16.90M | ($66.10M) | ($101.43M) | ($133.28M) | ($95.95M) | ($130.26M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $21.0K | $0 | $715.0K | $0 | $0 |
| Net Income | $29.82M | ($47.73M) | ($112.96M) | ($5.00M) | ($95.76M) | ($128.69M) |
| EPS - Basic | $2.42 | ($5.12) | ($1.95) | ($1.73) | - | - |
| EPS - Diluted | $2.42 | ($6.58) | ($1.95) | ($1.73) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.30M | $77.97M | $39.27M | $33.99M | $108.38M | $217.43M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $879.0K | $2.99M | $3.23M | $1.14M | $2.37M | $4.72M |
| Current Assets | $55.05M | $81.88M | $83.91M | $181.01M | $191.91M | $219.56M |
| Total Assets | $61.78M | $92.33M | $84.56M | $228.47M | $211.72M | $263.74M |
| Current Liabilities | $11.35M | $16.46M | $11.57M | $22.58M | $17.23M | $22.66M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $19.76M | $86.66M | $11.57M | $50.49M | $42.07M | $67.74M |
| Stockholders' Equity | $42.01M | $5.67M | $72.99M | $177.98M | $169.65M | $196.00M |
| Retained Earnings | ($204.99M) | ($234.81M) | ($542.10M) | ($429.14M) | ($424.13M) | ($328.37M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($33.54M) | ($67.72M) | ($96.23M) | ($113.66M) | ($109.75M) | ($94.33M) |
| Investing Cash Flow | $7.00M | $19.93M | $101.33M | $36.72M | ($50.79M) | $204.90M |
| Financing Cash Flow | ($3.13M) | $95.14M | $184.0K | $596.0K | $52.17M | $53.09M |
| CapEx | $0 | $75.0K | $228.0K | $1.28M | $2.40M | $3.73M |
| Free Cash Flow | ($33.54M) | ($67.79M) | ($96.46M) | ($114.95M) | ($112.15M) | ($98.06M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 31.5% | - | -8774.1% | -4154.6% | -282.4% | -4821.0% |
| EBITDA margin | 32.2% | - | -8724.1% | -4114.3% | -257.9% | -4526.2% |
| Net margin | 55.5% | - | -9771.7% | -156.0% | -281.9% | -4762.9% |
| Free cash flow margin | -62.4% | - | -8344.1% | -3583.1% | -330.1% | -3629.3% |
| FCF / Net income | -1.12 | 1.42 | 0.85 | 22.97 | 1.17 | 0.76 |
| R&D / Revenue | 35.6% | - | 5363.5% | 3065.8% | 274.0% | 3715.5% |
| SG&A / Revenue | 32.9% | - | 2703.8% | 1188.8% | 108.4% | 1205.5% |
| Effective tax rate | 0.0% | - | - | - | - | - |
| Return on assets | 48.3% | -51.7% | -133.6% | -2.2% | -45.2% | -48.8% |
| Return on equity | 71.0% | -841.1% | -154.8% | -2.8% | -56.4% | -65.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.85 | 4.97 | 7.25 | 8.02 | 11.14 | 9.69 |
| Quick ratio | 4.85 | 4.97 | 7.25 | 8.02 | 11.14 | 9.69 |
| Cash ratio | 4.26 | 4.74 | 3.39 | 1.51 | 6.29 | 9.60 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.47 | 16.27 | 1.16 | 1.28 | 1.25 | 1.35 |
| Liabilities / Assets | 0.32 | 0.94 | 0.14 | 0.22 | 0.20 | 0.26 |
| Efficiency | ||||||
| Asset turnover | 0.87 | 0.00 | 0.01 | 0.01 | 0.16 | 0.01 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | -100.0% | -64.0% | -90.6% | 1157.3% | 62.2% |
| Revenue CAGR (3y) | 155.9% | - | -24.6% | 24.4% | 109.7% | - |
| Revenue CAGR (5y) | 81.9% | - | -20.7% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 34.8% | 23.9% | -38.9% | 26.3% | -18.5% |
| Net income growth (YoY) | - | 57.7% | -2157.0% | 94.8% | 25.6% | -23.8% |
| EPS growth (YoY) | - | -237.4% | -12.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 50.5% | 29.7% | 16.1% | -2.5% | -14.4% | 13.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 640.3% | -92.2% | -59.0% | 4.9% | -13.4% | -24.2% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.31
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Homology Medicines against the 5 most active filers in the same SIC group.